#Spain #Valencia #Implantica #RefluxStop™ #GERD

Implantica's Expansion of RefluxStop™ Treatment in Spain

Implantica AG, a pioneering medtech company known for its cutting-edge medical devices, recently announced the expansion of its RefluxStop™ treatment centers in Spain. This initiative aims to improve access to innovative care for patients suffering from gastroesophageal reflux disease (GERD). The device targets a significant patient demographic, with an estimated one billion individuals affected by this condition worldwide.

New Center Opened in Valencia

The Hospital Vithas 9 de Octubre in Valencia is now the latest institution to offer the RefluxStop™ procedure, marking a significant milestone in the expansion process. Known for its advanced Digestive Endoscopy Unit, the hospital has committed to embracing innovative treatment options. Dr. Barrasa led the first RefluxStop™ surgery at this facility, highlighting the demand for effective surgical solutions with fewer adverse effects.

Dr. Barrasa stated, “Thanks to the surgical team's remarkable efforts, we successfully conducted our initial RefluxStop™ procedure. With the rising demand in Valencia and across Spain, patients are actively seeking out surgical interventions that minimize discomfort post-operation.” The uniqueness of the RefluxStop™ device lies in its ability to mitigate common postoperative symptoms typically associated with traditional anti-reflux surgeries.

The Significance of RefluxStop™

RefluxStop™ stands out in the field of GERD treatment due to its innovative mechanism of action. Unlike conventional surgeries that encircle the esophagus and can lead to complication such as swallowing difficulties, RefluxStop™ restores the lower esophageal sphincter to its natural position, enhancing the patient's quality of life.

Implantica’s CEO and the device’s inventor, Dr. Peter Forsell, expressed pride in the collaborative efforts at the Hospital Vithas 9 de Octubre. He emphasized the urgency of providing better surgical options for the increasing number of GERD patients, particularly as prolonged use of proton pump inhibitors (PPIs) can pose serious health risks.

With the introduction of this center, there are now 13 RefluxStop™ facilities across Spain, reflecting a robust commitment to improving the surgical landscape for GERD treatment. This aligns with the company's vision of transforming patient outcomes through advanced medical technology.

Innovative Approaches to Healthcare

Implantica remains at the forefront of innovation in the healthcare industry, with its RefluxStop™ product representing a potential paradigm shift in the treatment of acid reflux diseases. The company's focus is not just on surgical solutions but also on integrating eHealth technologies to monitor health parameters and manage treatments remotely.

In conclusion, the launch of the RefluxStop™ procedure at Hospital Vithas 9 de Octubre marks a vital step in addressing the rising needs of GERD patients across Spain. As more surgical centers adopt this advanced treatment, Implantica is set to redefine care standards for those suffering from this widespread condition. The future of GERD management looks promising with the continued innovation and expansion of Implantica’s RefluxStop™ initiative.

Additional Information

For further inquiries or to learn more about the RefluxStop™ procedure and its availability across Spain, interested parties can reach out to Nicole Pehrsson, Chief Corporate Affairs Officer at Implantica, or visit their official website for updates on their projects.